HAS Healthcare Advanced Synthesis in Biasca celebrates 40 years of excellence in the development and production of chemical-pharmaceutical active ingredients, with innovation and sustainability at the heart of the company’s development
This anniversary celebrates a journey of four decades filled with challenges, transformations, growth, and successes
Biasca, Switzerland – October 17, 2024
Founded in Biasca by Gabriele Pietro Braglia and starting its production in 1984 as a small chemical-pharmaceutical factory with an ambitious vision, today, HAS Healthcare Advanced Synthesis (HAS) is a global excellence, the result of targeted and constant investments, the perseverance of the Management, and the commitment and professionalism of all employees.
“In its forty years of activity, HAS has built and consolidated an international reputation in the development and production of pharmaceutical active ingredients (API), highly active ingredients (HPAPI), and high-quality anticancer compounds. Thanks to our expertise and attention to detail, we have become one of the reference companies in the sector, offering exclusive and personalized solutions to pharmaceutical and biotechnological companies, with the aim of improving the quality of life of patients,” explains Gabriele Pietro Braglia, Founder and Chairman of HAS Healthcare Advanced Synthesis.
“Over the years, HAS has continued to invest in its plant and the territory; in the last 10 years, over 100 million CHF have been invested, of which 40 million dedicated to the development and production of oncological molecules at the Biasca site. By focusing on cutting-edge technologies, we have improved both development and production capacities, maintaining a strong commitment to scientific innovation and sustainability, which represent our core values,” emphasizes Riccardo Braglia, Member of the Board of Directors of HAS Healthcare Advanced Synthesis.
Among the main initiatives is the connection to a district heating plant, managed by Nuova Energia Ticino, completed in 2019, which has allowed HAS to reduce CO2 emissions from fossil fuel use by 95%.
In 2020, HAS inaugurated a new global state-of-the-art anticancer substance production unit, completing the development, analysis, and production capacity to support our partners.
On the occasion of the 40th anniversary and with an eye to the future, driven by the growing demand for activities for the development and analysis of traditional and antitumor molecules, HAS inaugurated a new Quality Control Laboratory Center in April of this year. Equipped with cutting-edge technologies, the QC Laboratory Center is designed to rigorously test and guarantee the quality of traditional active pharmaceutical ingredients (API), highly active ingredients (HPAPI), and anticancer products. The laboratory was built following the most modern construction and sustainability standards.
In recent years, HAS has received numerous prestigious awards.
Since 2021, the company has achieved and maintained carbon neutrality. This significant milestone is the result of a decade of innovative and sustainable initiatives undertaken by HAS, driven by the commitment to decarbonize its activities along the entire value chain. The company has offset residual CO2 emissions through the purchase of certified credits (recognized Gold Standard), which support two projects in disadvantaged communities in Ethiopia.
HAS has also obtained the EcoVadis Gold Medal certification for 2023 (third consecutive year), placing the company in the top 2% of the most sustainable companies in the world. EcoVadis, a globally recognized provider of corporate sustainability ratings, awards the gold medal to companies that demonstrate exceptional performance across a range of sustainability criteria. This prestigious recognition highlights HAS’s constant commitment to corporate social responsibility (CSR) and sustainable business practices.
The entry of the fourth generation of the Braglia family into HAS Healthcare Advanced Synthesis (HAS), represented by the grandchildren Gabriele Edoardo and Giacomo Braglia, who join the Founder and President Gabriele Pietro Braglia and his son, and Member of the Board of Directors, Riccardo Braglia, demonstrates how family values and traditions can be successfully passed on over time, always keeping the family’s legacy alive.
“We look to the past with pride and gratitude, living the present with the awareness that HAS has become an important leader in the chemical-pharmaceutical industry, a constantly growing global reality. Our sector is highly competitive, but in the spirit of our company, we are ready to face current and future challenges with determination, confidence, and resilience,” emphasizes Waldo Mossi, CEO of HAS Healthcare Advanced Synthesis.
People are the beating heart of HAS. With great enthusiasm, on September 28th, 2024, we celebrated forty years of excellence and dreams achieved together with our employees, acknowledging their precious contributions and dedication with a day full of events and recognitions. With an eye to the future, we continue to work and evolve together.
For more information visit our website https://www.hashealthcare.com/ and follow us on Linkedin
Contact Press Office
HAS Healthcare Advanced Synthesis
Biasca, Switzerland
Giacomo Braglia
Tel: +41 (0) 91 873 94 00
Email: [email protected]